Results for tag: "HER2 Antibodies"

The HER2 (human epidermal growth factor receptor 2) antibodies market represents a specialized segment within the broader immune disorders drugs sector. These antibodies are primarily used in the treatment of certain types of cancer, most notably HER2-positive breast cancers, in which the HER2 protein is overexpressed, leading to cancer growth and spread. While the traditional focus of HER2 antibodies has been in oncology, their role in immune disorders is an emerging area of interest. Researchers are investigating the potential for HER2-targeting antibodies to modulate immune responses, which could be applicable in treating autoimmune conditions or other immune-related disorders. The development of such therapeutic agents often involves monoclonal antibodies engineered to recognize and bind specifically to the HER2 protein. Within this market, there are distinct companies with a presence, each contributing to advancements in therapy and research. Genentech, a member of the Roche Group, is a well-known player due to its development of pioneering HER2-targeted therapies. Another key player is GlaxoSmithKline, which also offers treatments in this domain. AstraZeneca and Daiichi Sankyo have collaborated to produce novel HER2-targeting therapies. Additionally, Puma Biotechnology focuses on the development of drugs for the treatment of HER2-positive breast cancer. These companies, among others, contribute to the dynamic landscape of the HER2 antibodies market within the realm of immune disorders drugs. Show Less Read more